Skip to main content

Table 3 PPI in SPCR projects, by study design, health condition, population and population age

From: The extent, quality and impact of patient and public involvement in primary care research: a mixed methods study

 

Projects (Grant applications)

Projects with evidence of PPI in developing the grant application

(N = 200)

Projects with evidence of plans for PPI during the study in the grant application (N = 200)

Projects (Annual/ Final Reports)a

Projects with evidence of PPI reported in annual/final reports (N = 181)

 

n

(%)

n

(%)

(Relative %)b

n

(%)

(Relative %)b

n

(%)

n

(%)

(Relative %)c

All Projects

200

(100)

47

(23.5)

 

113

(56.5)

 

181

(181)

83

(46.1)

 

Study Design

 Mixed methods

47

(23.5)

15

(7.5)

(31.9)

30

(15.0)

(63.8)

39

(21.5)

24

(13.3)

(61.5)

 Qualitative

36

(18.0)

9

(4.5)

(25.0)

23

(11.5)

(63.9)

30

(16.6)

17

(9.4)

(56.7)

 Longitudinal cohort

29

(14.5)

5

(2.5)

(17.2)

18

(9.0)

(62.1)

29

(16.0)

11

(6.1)

(37.9)

 Intervention trial

25

(12.5)

6

(3.0)

(24.0)

15

(7.5)

(60.0)

23

(12.7)

14

(7.7)

(60.9)

 Systematic reviews

17

(8.5)

2

(1.0)

(11.8)

7

(3.5)

(0.0)

17

(9.4)

2

(1.1)

(11.8)

 Retrospective cohort

13

(6.5)

2

(1.0)

(15.4)

4

(2.0)

(30.8)

13

(7.2)

3

(1.7)

(23.1)

 Secondary analysis

8

(4.0)

0

(0.0)

(0.0)

4

(2.0)

(50.0)

8

(4.4)

3

(1.7)

(37.5)

 Cross sectional

7

(3.5)

4

(2.0)

(57.1)

3

(1.5)

(42.9)

7

(3.9)

4

(2.2)

(57.1)

 Methodological

5

(2.5)

1

(0.5)

(20.0)

4

(2.0)

(80.0)

4

(2.2)

1

(0.6)

(25.0)

 Case control

4

(2.0)

0

(0.0)

(0.0)

1

(0.5)

(25.0)

3

(1.7)

0

0

(0.0)

 Multi-stage studyd

4

(2.0)

2

(1.0)

(50.0)

2

(1.0)

(50.0)

2

(1.1)

2

(1.1)

(100)

 Individual participant meta analysis

3

(1.5)

0

(0.0)

(0.0)

1

(0.5)

(33.3)

2

(1.1)

1

(0.6)

(50.0)

 Othere

2

(1.0)

1

(0.5)

(50.0)

1

(0.5)

(50.0)

4

(2.2)

2

(1.1)

(50.0)

Health Condition Under Study

 General Health

28

(14.0)

9

(4.5)

(32.1)

14

(7.0)

(50.0)

22

(12.2)

9

(0.0)

(40.9)

 Cardiovascular

27

(13.5)

4

(2.0)

(14.8)

16

(8.0)

(59.3)

28

(15.5)

10

(5.5)

(35.7)

 Mental Health

21

(10.5)

5

(2.5)

(23.8)

12

(6.0)

(57.1)

17

(9.4)

11

(6.1)

(64.7)

 Cancer

16

(8.0)

7

(3.5)

(43.8)

8

(4.0)

(50.0)

16

(8.8)

10

(5.5)

(62.5)

 Metabolic and Endocrine

14

(7.0)

1

(0.5)

(7.1)

6

(3.0)

(42.9)

16

(8.8)

9

(5.0)

(56.3)

 Musculoskeletal

14

(7.0)

3

(1.5)

(21.4)

6

(3.0)

(42.9)

13

(7.2)

6

(3.3)

(46.2)

 Respiratory

13

(6.5)

3

(1.5)

(23.1)

6

(3.0)

(46.2)

12

(6.6)

5

(2.8)

(41.7)

 Multimorbidity

7

(3.5)

0

(0.0)

(0.0)

1

(0.5)

(14.3)

8

(4.4)

3

(1.7)

(37.5)

 Stroke

7

(3.5)

1

(0.5)

(14.3)

3

(1.5)

(42.9)

5

(2.8)

2

(1.1)

(40.0)

 Infection

5

(2.5)

1

(0.5)

(20.0)

3

(1.5)

(60.0)

5

(2.8)

1

(5.0)

(20.0)

 Renal and Urogenital

5

(2.5)

2

(1.0)

(40.0)

5

(2.5)

(100)

5

(2.8)

3

(1.7)

(60.0)

 Reproductive Health and Childbirth

5

(2.5)

2

(1.0)

(40.0)

5

(2.5)

(100)

5

(2.8)

4

(2.2)

(80.0)

 Neurological

3

(1.5)

0

(0.0)

(0.0)

3

(1.5)

(100)

1

(0.6)

1

(0.6)

(100)

 Cancer, Mental Health

1

(0.5)

1

(0.5)

(100)

0

(0.0)

(0.0)

1

(0.6)

1

(0.6)

(100)

 Inflammatory and Immune System

1

(0.5)

0

(0.0)

(0.0)

0

(0.0)

(0.0)

0

(0.0)

0

(0.0)

 

 Oral and Gastrointestinal

1

(0.5)

0

(0.0)

(0.0)

0

(0.0)

(0.0)

1

(0.6)

0

(0.0)

(0.0)

 Skin

1

(0.5)

1

(0.5)

(100)

1

(0.5)

(100)

1

(0.6)

1

(0.6)

(100)

 Otherf

31

(15.5)

7

(3.5)

(22.6)

24

(12.0)

(77.4)

23

(12.7)

8

(4.4)

(34.8)

Study population

 Patients

134

(67.0)

26

(13.0)

(19.4)

68

(34.0)

(50.7)

123

(68.0)

54

(29.8)

(43.9)

 Patients & HCPs

37

(18.5)

11

(5.5)

(29.7)

24

(12.0)

(64.9)

31

(17.1)

20

(11.0)

(64.5)

 Healthcare professionals (HCPs)

15

(7.5)

5

(2.5)

(33.3)

10

(5.0)

(66.7)

8

(4.4)

3

(1.7)

(37.5)

 General public

13

(6.5)

5

(2.5)

(38.5)

10

(5.0)

(76.9)

15

(8.3)

7

(3.9)

(46.7)

 Carers

1

(0.5)

0

(0.0)

(0.0)

1

(0.5)

(100)

1

(0.6)

0

(0.0)

(0.0)

Study population age

 Unspecified

93

(46.5)

19

(9.5)

(20.4)

54

(27.0)

(58.1)

83

(45.9)

35

(19.9)

(43.4)

 Adult (18+ years)

89

(44.5)

24

(12.0)

(27.0)

50

(25.0)

(56.2)

83

(45.9)

42

(23.2)

(50.6)

 Adult and Children

11

(5.5)

4

(2.0)

(36.4)

7

(3.5)

(63.6)

9

(5.0)

5

(2.8)

(55.6)

 Children and young adults (0–17 years)g

7

(3.5)

0

(0.0)

(0.0)

2

(1.0)

(28.6)

6

(3.3)

1

(0.6)

(16.7)

  1. aIncluded one project whose data on PPI was obtained from an SPCR poster
  2. bPercentage relative to the number of projects in each category in grant applications
  3. cPercentage relative to the number of projects in each category in annual/final reports
  4. dMulti-stage studies included case control and intervention trial (1), cross sectional and longitudinal cohort (1), systematic review and longitudinal cohort (1), systematic review and secondary analysis
  5. eIncluded projects to set up and maintain a SPCR PPI group (1) and a preliminary descriptive study (1)
  6. fConditions not classified under the Health Research Classification System [24]
  7. gIt was not always possible to determine the ages or age range of children from the study documentation. Sometimes, ages were provided, sometimes the documentation referred to ‘children’. So we have assumed children and young adults to be 17 and under
Back to article page

Research Involvement and Engagement

ISSN: 2056-7529

Contact us